Home › Research › Topics › rationale
rationale
5 studies tagged rationale, dated 2007-01-01 to 2024-10-19. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study 2024-10-19
- A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design 2023-12-29
- A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design 2023-05-26
Studies
5 studies carry this tag.
Date range
2007 to 2024
Top journals
- Mechanisms of ageing and development 2
- Alzheimer's research & therapy 1
- Chronobiology international 1
- Progress in brain research 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
69/100
In TAP-TAU, we will investigate the added clinical value of tau-PET in a real-world clinical setting, including memory clinic patients with diagnostic uncertainty after routine work-up.
-
This feasibility study is anticipated to provide the basis for a multi-center large-scale randomized clinical trial (RCT) of the cognitive benefits of the combination of INI with semaglutide in individuals enriched for CVD and at high dementia risk.
-
This feasibility study is anticipated to provide the basis for a multi-center large-scale randomized clinical trial of the cognitive benefits of the combination of INI with dulaglutide in individuals enriched for CVD and at high dementia risk.
-
The most pressing need in Parkinson's disease (PD) clinical practice is to identify agents that might slow down, stop or reverse the neurodegenerative process of Parkinson's disease and therefore avoid the onset of the most disabling, dopa-refractory symptoms of the disease.
-
ABPM reveals the significant circadian variation in BP, which in most individuals presents a morning increase, small post-prandial decline, and more extensive lowering during nocturnal rest.